Published in Patient Prefer Adherence on July 21, 2010
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Use of oral corticosteroids and risk of fractures. J Bone Miner Res (2000) 4.75
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int (2007) 3.50
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int (2002) 3.45
Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone (2005) 3.13
Osteoporosis: a still increasing prevalence. Bone (2006) 2.89
The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int (2004) 2.88
Treatment of postmenopausal osteoporosis. N Engl J Med (1998) 2.83
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Malignant bone pain: pathophysiology and treatment. Pain (1997) 2.75
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A (2006) 2.73
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum (2001) 2.59
Prevention and management of osteoporosis. World Health Organ Tech Rep Ser (2003) 2.48
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) (2000) 2.13
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone (2007) 1.97
The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int (2003) 1.97
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone (2007) 1.94
Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study. Osteoporos Int (2003) 1.91
Bisphosphonates: from bench to bedside. Ann N Y Acad Sci (2006) 1.82
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica (2006) 1.71
Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res (2000) 1.70
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials (2005) 1.61
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med (2006) 1.55
Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol (2004) 1.43
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone (2003) 1.34
Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res (2005) 1.30
Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int (2008) 1.24
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int (2007) 1.21
Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res (2009) 1.17
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res (2007) 1.16
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc (2010) 1.16
The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab (2008) 1.14
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metab (2005) 1.08
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone (2004) 1.03
Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest (2002) 1.01
Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop (2005) 1.00
Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res (2010) 0.99
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int (2005) 0.99
Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol (2009) 0.99
Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging (2006) 0.93
Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int (2007) 0.92
Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol (2009) 0.92
Prevention, screening, and management of osteoporosis: an overview of the current strategies. Postgrad Med (2009) 0.91
Zoledronic acid: a new parenteral bisphosphonate. Clin Ther (2003) 0.91
Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Expert Rev Anticancer Ther (2009) 0.89
A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab (2005) 0.86
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Male osteoporosis: new insights in an understudied disease. Curr Opin Rheumatol (2008) 0.86
Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporos Int (2002) 0.85
Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab (2003) 0.84
Zoledronic acid: a review of its use in the treatment of Paget's disease of bone. Drugs (2007) 0.83
Zoledronic acid: a review of its use in the treatment of osteoporosis. Drugs Aging (2008) 0.82
Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther (2000) 0.82
Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs (2003) 0.81
Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica (2008) 0.80
Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab (2009) 0.80
Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol (2006) 0.79
Osteoporosis: challenges and new opportunities for therapy. Curr Opin Drug Discov Devel (2002) 0.78
Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis. Ann Hematol (2008) 0.77
Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations. Clin Interv Aging (2008) 0.77